^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABT-101

    i
    Other names: ABT-101, DBPR-112, DBPR 112, DBPR112
    Associations

    News

    Trials
    Company:
    Anbogen Therap, National Health Research Institutes
    Drug class:
    EGFR inhibitor, HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Anbogen Therapeutics, Inc. | Phase classification: P1b/2 --> P1/2 | N=121 --> 61
    Phase classification • Enrollment change • HER2 exon 20 • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    ABT-101
    over1year
    Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients (clinicaltrials.gov)
    P1b/2, N=121, Recruiting, Anbogen Therapeutics, Inc. | Trial completion date: Nov 2023 --> May 2027 | Trial primary completion date: Apr 2023 --> Nov 2026
    Trial completion date • Trial primary completion date • HER2 exon 20 • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    ABT-101